Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation
Health Technology Assessment
NIHR Health Technology Assessment Programme
To assess the clinical effectiveness and cost-effectiveness of bevacizumab, combined with interferon (IFN), sorafenib tosylate, sunitinib and temsirolimus in the treatment of people with advanced and/or metastatic renal cell carcinoma (RCC).
addresses: Peninsula Technology Assessment Group, Peninsula College of Medicine and Dentistry, University of Exeter, UK.
types: Journal Article; Review
Published version. Copyright © 2010 NIHR Health Technology Assessment Programme
Health Technology Assessment, 2010, Vol. 14, Issue 2, pp. 1 - iv
Place of publication